Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel

By Chatel-Chaix Laurent   Baril Martin   Lamarre Daniel  

Viruses, Vol. 2, Iss. 8, 2010-08 ,pp. : 1752-1765

MDPI

Access to resources Recommend Favorite

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

By Kanda Tatsuo   Yasui Shin   Nakamura Masato   Suzuki Eiichiro   Arai Makoto   Ooka Yoshihiko   Ogasawara Sadahisa   Chiba Tetsuhiro   Saito Tomoko   Haga Yuki   Takahashi Koji   Sasaki Reina   Wu Shuang   Nakamoto Shingo   Tawada Akinobu   Maruyama Hitoshi   Imazeki Fumio   Kato Naoya   Yokosuka Osamu  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-04 ,pp. : 906-906

MDPI

Access to resources Recommend Favorite

MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and Therapy

By Gupta Archana   Swaminathan Gokul   Martin-Garcia Julio   Navas-Martin Sonia  

Viruses, Vol. 4, Iss. 11, 2012-10 ,pp. : 2485-2513

MDPI

Access to resources Recommend Favorite

Different Culture Metabolites of the Red Sea Fungus Fusarium equiseti Optimize the Inhibition of Hepatitis C Virus NS3/4A Protease (HCV PR)

By Hawas Usama W.   Al-Farawati Radwan   Abou El-Kassem Lamia T.   Turki Adnan J.  

Marine Drugs, Vol. 14, Iss. 10, 2016-10 ,pp. : 190-190

MDPI

Access to resources Recommend Favorite

Claudin‐1 gene variants and susceptibility to hepatitis C infection in HIV‐1 infected intravenous drug users (an ANRS case‐control study)

By  

JOURNAL OF MEDICAL VIROLOGY, Vol. 87, Iss. 4, 2015-04 ,pp. : 619-624

John Wiley & Sons Inc

Access to resources Recommend Favorite